Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing